Digital Endpoints Resource Series
Enhancing Parkinson’s Disease Research with Wearable DHTs
Enhancing Parkinson’s Disease Research with Wearable DHTs
Drug development for Parkinson's disease (PD) has been challenging, hindered in part by the lack of adequate clinical endpoints to measure disease progression and detect drug efficacy. Motor and non-motor symptoms of PD can affect patients in many ways, including their physical functioning, mobility, and sleep.
With the advent of sensor-based digital health technologies (DHTs), we now have an unprecedented opportunity to remotely and continuously assess how study participants in Parkinson’s disease research function in their daily lives.
This digital endpoints guide provides information on wearable DHT use in PD clinical trials and relevant regulatory guidance, a list of digital endpoints available for PD trials, and opportunities to advance PD research with wearable DHTs, including:
- Assessing acute changes in specific PD symptoms with continuous, objective data
- Collecting evidence of health benefits for PD trials through novel digital endpoints
- More reliably characterizing patients' symptoms to identify subgroups to support enrollment
- Supporting patient-centric drug development with easy-to-use wrist-worn technology
- Passively examining cardinal symptoms, gait and mobility, sleep behavior, and vital signs in the patient’s natural environment
Filling Gaps in Parkinson’s Disease Measures with DHTs
Learn more about how continuous, real-world data from medical-grade wearables for Parkinson’s disease research can enable more objective and sensitive measures to adequately capture disease fluctuations and progression over time:
- Digital Health Monthly Webinar: Address Unmet Measurement Needs in Parkinson’s Disease with Wearable DHTs
- Patient-focused Digital Measures Report: Parkinson's disease
- ActiGraph and PKG Health Partner to Improve Outcomes in Neurology Trials
- ActiGraph and Indivi Announce Partnership to Advance Precision Neuroscience Trials
